

HB 2407 -- ADVISORY COUNCIL ON RARE DISEASES AND PERSONALIZED
MEDICINE

SPONSOR: Ruth

This bill establishes the "Advisory Council on Rare Diseases and Personalized Medicine" to serve as an expert advisory committee to the Drug Utilization Review Board. The advisory council shall be made up of health care professionals as specified in the bill. The first meeting of the advisory council shall be no later than February 28, 2019, and following the first meeting, the advisory council will meet upon request.

The bill requires the review board to seek the input of the advisory council on a variety of topics, as specified in the bill. Any recommendation of the advisory council must be made in writing and during a public hearing. When the review board makes a coverage decision that contradicts the recommendations of the advisory council the review board shall clarify the reasoning behind the decision in a format that is available to the public.

This bill requires all advisory council members to annually sign a conflict of interest statement and specifies that at least 20% of the members may not have a conflict of interest to any insurer, pharmaceutical benefits manager, or pharmaceutical manufacturer.